RE:Ryhigh's numbersWell I modeled out the firms financial statements from inception based on public record.
So i have more flexbility in terms of getting down to the nitty gritty ratios and other metrics. To be upfront you have to treat this company differently than a normal pharma company. They are a roll up no question about it and therefore liquidity, and solvency needs to be scrutizined.
To answer your question in my analytics I do not see the beating at quarter end if Sterling continues to depreciate. I've used 1.10 for Q4 and 1.21 for Q3.
I think 1.10 is likely. But we are more likely to see it next year after April unless Theresa may miracolously reverses on Brexit (not likely)